Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment

Autor:	Surinder K. Batra, Fen Fen Lin, Li Zhang, Ralph J. Hauke, Rachel Schutte, Thomas L. Davis, Ming Fong Lin, Stanislav Zelivianski, Jeffrey S. Davis
Rok vydání:	2009
Předmět:	Male Oncology Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Time Factors Combination therapy Receptor ErbB-2 bcl-X Protein Down-Regulation Apoptosis Biology Deoxycytidine Article chemistry.chemical_compound ErbB Cell Line Tumor Internal medicine Antineoplastic Combined Chemotherapy Protocols LNCaP medicine Humans Cytotoxic T cell Benzothiazoles Extracellular Signal-Regulated MAP Kinases Protein Kinase Inhibitors Cell Proliferation bcl-2-Associated X Protein Flavonoids Dose-Response Relationship Drug Prostatic Neoplasms Cancer Tyrphostins medicine.disease Gemcitabine Proto-Oncogene Proteins c-bcl-2 chemistry Cancer cell Androgens Quinazolines Cancer research Growth inhibition medicine.drug
Zdroj:	Cancer Letters. 285:58-65
ISSN:	0304-3835
DOI:	10.1016/j.canlet.2009.04.041
Popis:	We examined the efficacy of combination treatments utilizing cytotoxic drugs plus inhibitors to members of the ErbB - ERK signal pathway in human prostate cancer (PCa) LNCaP C-81 cells. Under an androgen-reduced condition, 50 nM gemcitabine caused about 40% growth suppression on C-81 cells. Simultaneous treatment of gemcitabine plus 10 µM AG825 produced 60% suppression (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7e893135c2d556f55069d628441c063 https://doi.org/10.1016/j.canlet.2009.04.041 Zobrazit plný text záznamu Full Text from ScienceDirect